Health Aadi Bioscience Announces Data Presentation on incidence of TSC1 and TSC2 Alterations in Advanced… James Pereira Apr 10, 2022 - First rigorous analysis estimates TSC1 and TSC2 definite impact alteration incidence in U.S. as approximately 12,000… Read More...
Health Aadi Bioscience to Present at 2022 H.C. Wainwright BioConnect Virtual Conference James Pereira Jan 5, 2022 LOS ANGELES, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Aadi Bioscience, Inc. (“Aadi”), a biopharmaceutical company focusing… Read More...
Health Aadi Bioscience Announces FDA Approval of its First Product FYARRO™ for Patients with Locally… James Pereira Nov 23, 2021 FYARRO is the first and only approved therapy for adults for the treatment of malignant PEComa, an ultra-rare and… Read More...
Health Aadi Bioscience Presents Two Abstracts on FYARRO (nab-Sirolimus) at the Annual Meeting of the… James Pereira Nov 14, 2021 In an Expanded Access Program, advanced malignant PEComa patients who previously progressed on other mTOR inhibitors… Read More...
Health Aadi Bioscience Appoints Loretta Itri as Chief Medical Officer James Pereira Oct 25, 2021 LOS ANGELES, Oct. 25, 2021 (GLOBE NEWSWIRE) -- Aadi Bioscience, Inc. (“Aadi”) (Nasdaq: AADI), a clinical-stage… Read More...
Health Aadi Bioscience Announces Publication of its Phase 2 Registrational (AMPECT) Trial of nab-Sirolimus… James Pereira Oct 23, 2021 LOS ANGELES, Oct. 22, 2021 (GLOBE NEWSWIRE) -- Aadi Bioscience, Inc. (“Aadi”) (Nasdaq: AADI), a clinical-stage… Read More...
LifeStyle An appetising Aadi affair Taner Halicioglu Aug 2, 2021 Express News Service CHENNAI: Intricately patterned kolams on the doorways of houses, new clothes… Read More...
Health Aadi Bioscience Presents Emerging Data for FYARRO™ in Patients with Solid Tumors Harboring TSC1 or… James Pereira Jun 6, 2021 Five of six mTOR inhibitor-naïve patients with TSC1 or TSC2 inactivating alterations achieved confirmed partial… Read More...